Efficacy and safety of the ophthalmic solution travoprost in patients with primary open-angle glaucoma or ocular hypertension [Eficacia y seguridad de la soluci�n oft�lmica de travoprost en pacientes con glaucoma primario de �ngulo abierto o hipertensi�n ocular]

Purpose: To evaluate the safety and efficacy of travoprost, 0.004% solution, when administered during three months for the treatment of elevated intraocular pressure (IOP) in Mexican patients. Methods: Thirty Mexican patients, with either open-angle glaucoma or ocular hypertension participated in the study. Patients who qualified began a washout period. Travoprost, 0.004% solution, was applied topically once a day for three months. Results: Travoprost 0.004%, produced a clinically and statistically significant reduction in IOP (P < 0.0001). Maximal decrease in pressure occurred within two weeks and remained essentially unchanged for the remainder of the study. Mean reduction in IOP was between 8.2 and 8.9 mmHg representing decreases of 29.6% to 32.7%. Travoprost was well tolerated. There were no serious adverse events. The most frequent events were ocular hyperaemia (63.3%), flare (16.7%), burning (13.3%), blepharitis (10%), ocular pain (10.0%) and ocular pruritus (10.0%). Conclusions: Travoprost, 0.004%, administered topically once a day is safe and effective in lowering IOP in patients with open-angle glaucoma and ocular hypertension